Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.40 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30977785 | 1.00 | RAPGEF4 (0.54) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1010790 | 0.98 | RAPGEF4 (0.56) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29401670 | 0.98 | RAPGEF4 (0.56) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19837651 | 0.93 | RAPGEF4 (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL9850864 | 0.87 | MEN1 (0.56) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL839579 | 0.81 | RAPGEF4 (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31082291 | 0.81 | RAPGEF4 (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12819946 | 0.79 | RAPGEF4 (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL838148 | 0.78 | RAPGEF4 (0.54) | RAPGEF4MEN1KMT2AALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL2863950 | 0.78 | RAPGEF4 (0.56) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | claimed |
| CN-116887609-A | Perovskite thin film layer and preparation method thereof, perovskite silicon laminated solar cell and preparation method thereof | 通威太阳能（成都）有限公司 | 2023-10-13 | — | — | CN | claimed |
| EP-3241824-B1 | TRIFLUOROACETHYDRAZIDE COMPOUND AS WELL AS PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARING A MEDICAMENT | GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) | 2021-04-28 | — | — | EP | claimed |
| CN-112279780-A | Industrial preparation method of broad-spectrum neuroprotective active phenylhydrazide compound | 陈开云 | 2021-01-29 | — | — | CN | claimed |
| US-10308616-B2 | Trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof | GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) | 2019-06-04 | — | — | US | claimed |
| US-20180346430-A1 | TRIFLUOROACETYL HYDRAZIDE COMPOUNDS AND METHODS OF PREPARATION AND USES THEREOF | GUANGZHOU MAGPIE PHARMACEUTICALS CO., LTD. (CN) | 2018-12-06 | — | — | US | claimed |
| CN-106749288-B | N- (substituted-phenyl) Bi Zuo Bing fraxinellones analog derivative, preparation method and application | 郑州大学 | 2018-07-10 | — | — | CN | claimed |
| CN-106749288-A | N (substituted benzene) base Bi Zuo Ji fraxinellones analog derivative, its preparation method and application | 郑州大学 | 2017-05-31 | — | — | CN | claimed |
| CN-105801496-A | Trifluoroacetyl hydrazine compound, preparation method thereof and application thereof in pharmacy | 广州喜鹊医药有限公司 | 2016-07-27 | — | — | CN | claimed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-5942151-A | PREVENTING THE DISCOLORATION OF PRODUCING POLYMETHYLENEPOLYPHENYLENE POLYISOCYANATE BY ADDING AN ADDITIVE HYDRAZINE OR A HYDRAZINE DERIVATIVE | BAYER CORPORATION (US) | 1999-08-24 | — | — | US | claimed |
| EP-0918052-A1 | Improved polymeric mdi color | Bayer Corporation (US) | 1999-05-26 | — | — | EP | claimed |
| WO-2025020685-A1 | PEROVSKITE THIN FILM LAYER AND PREPARATION METHOD THEREFOR, AND PEROVSKITE SILICON STACKED SOLAR CELL AND PREPARATION METHOD THEREFOR | 通威太阳能（成都）有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2024177127-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 | 2024-08-29 | — | — | WO | disclosed |
| CN-117402140-A | Quinolone indole compound and preparation method and application thereof | 西南大学 | 2024-01-16 | — | — | CN | disclosed |
| CN-116887609-A | Perovskite thin film layer and preparation method thereof, perovskite silicon laminated solar cell and preparation method thereof | 通威太阳能（成都）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-4257952-A | PSYCHOTROPIC DRUGS, ANALGESICS, ANTIHISTAMINES | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346430-A1 | TRIFLUOROACETYL HYDRAZIDE COMPOUNDS AND METHODS OF PREPARATION AND USES THEREOF | MEF2D, BDNF, TFAM | GAA 285/4885HSP90AA1 1364/4885HDAC3 216/4885 |
| US-10308616-B2 | Trifluoroacetyl hydrazide compounds and methods of preparation and uses thereof | MEF2D, BDNF, TFAM | GAA 285/4885HSP90AA1 1364/4885HDAC3 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.